Leerink Swann reiterated their outperform score on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) in a analysis observe issued to buyers on Sunday morning. Leerink Swann at present has a $7.00 goal worth on the inventory.
Several different brokerages have additionally issued reviews on AUPH. Canaccord Genuity restated a purchase score and issued a $10.00 goal worth on shares of Aurinia Pharmaceuticals in a analysis word on Saturday, October eighth. FBR & Co set a $9.00 goal worth on Aurinia Pharmaceuticals and gave the corporate a purchase score in a analysis word on Wednesday, October 12th. HC Wainwright restated a purchase score and issued a $10.00 goal worth on shares of Aurinia Pharmaceuticals in a analysis word on Wednesday, October fifth. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a promote score to a maintain score in a analysis observe on Monday, November 21st. Finally, Mackie restated a purchase score and issued a $eight.00 goal worth on shares of Aurinia Pharmaceuticals in a analysis observe on Wednesday, November 2nd. One analysis analyst has rated the inventory with a maintain score and 6 have assigned a purchase score to the corporate’s inventory. Aurinia Pharmaceuticals presently has a consensus score of Buy and a mean goal worth of $7.79.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down 2.36% throughout buying and selling on Friday, reaching $2.89. The firm’s inventory had a buying and selling quantity of 583,285 shares. The inventory has a 50-day shifting common worth of $three.46 and a 200 day shifting common worth of $2.93. The firm’s market cap is $114.81 billion. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week excessive of $5.69.
TRADEMARK VIOLATION WARNING: This report was initially posted by BBNS and is the propert of of BBNS. If you’re viewing this report on one other publication, it was stolen and reposted in violation of United States & worldwide copyright & trademark law. The right model of this report could be learn at https://baseballnewssource.com/markets/aurinia-pharmaceuticals-auph-outperform-rating-reiterated-at-leerink-swann/263251.html.
Institutional buyers have just lately purchased and bought shares of the corporate. KCG Holdings Inc. acquired a brand new place in Aurinia Pharmaceuticals through the third quarter valued at roughly $153,00zero. Creative Planning bought a brand new place in Aurinia Pharmaceuticals in the course of the third quarter value about $181,00zero. Lombard Odier Asset Management USA Corp boosted its place in Aurinia Pharmaceuticals by 2.eight% within the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the corporate’s inventory value $283,00zero after shopping for a further 2,813 shares over the past quarter. Redmile Group LLC boosted its place in Aurinia Pharmaceuticals by 560.four% within the third quarter. Redmile Group LLC now owns 187,610 shares of the corporate’s inventory value $565,00zero after shopping for a further 159,200 shares over the past quarter. Finally, SG Americas Securities LLC bought a brand new place in Aurinia Pharmaceuticals in the course of the third quarter value about $1,123,00zero. Institutional buyers and hedge funds personal 10.67% of the corporate’s inventory.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based medical-stage biopharmaceutical firm working within the subject of nephrology and autoimmunity. The Company’s main enterprise is the event of a therapeutic drug to deal with autoimmune illnesses, particularly lupus nephritis (LN). It is concentrated on the event of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-era calcineurin inhibitors (CNI) to deal with sufferers bothered with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily – Enter your e mail tackle under to obtain a concise every day abstract of the newest information and analysts’ scores for Aurinia Pharmaceuticals Inc. and associated corporations with our FREE daily email newsletter.
Source link
The post Aurinia Pharmaceuticals' (AUPH) "Outperform" Rating Reiterated at Leerink Swann – BBNS appeared first on Utah Business Lawyer.
from
http://www.utbusinesslawyer.com/aurinia-pharmaceuticals-auph-outperform-rating-reiterated-at-leerink-swann-bbns/
No comments:
Post a Comment